How will risk be communicated on the Prostate Cancer iPRS™ report?
Each report will have a results summary indicating if the patient is at “increased risk” or “not increased risk” of developing prostate cancer in their lifetime. MyOme defines “increased risk” as an integrated lifetime risk of 25% or higher.
Each report will have a results summary indicating if the patient is at “increased risk” or “not increased risk” of developing prostate cancer in their lifetime. MyOme defines “increased risk” as an integrated lifetime risk of 25% or higher.
Integrated Risk: The patient’s personalized remaining lifetime prostate cancer risk based on the combination of genetic and clinical risk factors. Integrated 10-year risk is also reported for patients aged 40-70 years old.
Average Population Risk: The chance of developing prostate cancer in the remaining lifetime for a biological male of the same ancestry and age, with no family history of prostate cancer and average PRS. Average population 10-year risk is also reported for patients aged 40-70 years old.
Relative risk: Compares a patient’s lifetime chance of developing prostate cancer to that of the average person of the same ancestry who has no family history of the disease. It reflects how your genetic risk score (PRS) and family history together may increase or decrease your overall risk. For example, a relative risk of 2 would mean the your risk is about two-times higher than the average person of the same ancestry who has no family history of prostate cancer.